An injection capable of preventing HIV infection for six months has received approval from the US Food and Drug Administration (FDA). Gilead’s Yeztugo (lenacapavir) is now the longest-acting variant of pre-exposure prophylaxis (PrEP) for adults at risk of sexually acquired HIV. It functions by disrupting HIV’s capacity to create its outer protein shell (capsid) and […]
Read More